Intercept Pharmaceuticals (NASDAQ: ICPT) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Intercept Pharmaceuticals to similar companies based on the strength of its earnings, dividends, risk, valuation, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares Intercept Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intercept Pharmaceuticals -344.74% -176.51% -57.15%
Intercept Pharmaceuticals Competitors -5,322.24% -84.37% -35.66%

Earnings & Valuation

This table compares Intercept Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Intercept Pharmaceuticals $24.95 million -$412.83 million -3.71
Intercept Pharmaceuticals Competitors $290.27 million $35.99 million 51.64

Intercept Pharmaceuticals’ rivals have higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Intercept Pharmaceuticals and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intercept Pharmaceuticals 2 9 10 0 2.38
Intercept Pharmaceuticals Competitors 949 3398 11903 239 2.69

Intercept Pharmaceuticals currently has a consensus price target of $140.45, suggesting a potential upside of 155.97%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.95%. Given Intercept Pharmaceuticals’ higher possible upside, equities research analysts plainly believe Intercept Pharmaceuticals is more favorable than its rivals.

Insider and Institutional Ownership

73.8% of Intercept Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 4.5% of Intercept Pharmaceuticals shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Intercept Pharmaceuticals has a beta of -2.05, suggesting that its stock price is 305% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals’ rivals have a beta of 2.51, suggesting that their average stock price is 151% more volatile than the S&P 500.

Summary

Intercept Pharmaceuticals rivals beat Intercept Pharmaceuticals on 10 of the 13 factors compared.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.